Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 3.39%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth and improved profitability. Strategic initiatives and market expansion plans indicate a positive outlook, despite some challenges in specific segments like extremities and pending regulatory impacts.Company Guidance
During Axogen's 2024 fiscal year-end call, the company outlined several key financial metrics and future guidance. The full-year revenue for 2024 was reported at $187.3 million, marking a 17.8% increase from 2023. Specifically, the fourth quarter revenue grew to $49.4 million, a 15.1% rise compared to the previous year, with an 11% increase in unit volume and mix and a 4% increase in price. Gross profit for Q4 was $37.6 million, translating to a gross margin of 76.1%, up from 74.6% in Q4 2023. Operating expenses for the same period were $35.6 million, with sales and marketing expenses decreasing as a percentage of total revenue to 40.6% from 46.9% the previous year. The company achieved a net income of $0.4 million or $0.01 per share, compared to a net loss in Q4 2023. For 2025, Axogen projected a revenue growth range of 15% to 17% and gross margin between 73% and 75%, factoring in one-time BLA approval costs. They also plan to maintain positive cash flow throughout the year, aiming to self-fund their strategic initiatives.Strong Revenue Growth
Full year 2024 revenue was $187.3 million, a 17.8% increase compared to 2023. Fourth quarter revenue increased to $49.4 million, up 15.1% compared to the prior year.
Improved Financial Performance
Net income of $0.4 million or $0.01 per share, compared to a net loss of $3.9 million or $0.09 per share in Q4 2023. Adjusted net income for the quarter was $3.5 million or $0.07 per share.
Positive Cash Flow and Financial Position
Maintained cash flow positivity with a cash, cash equivalents, and investments balance of $39.5 million at the end of December 2024.
BLA Application Progress
Submitted the BLA for Avance Nerve Graft in Q3 2024 with expected approval in September 2025, potentially providing 12 years of market exclusivity.
Strategic Plan for Growth
Announced a new strategic plan targeting a $5 billion TAM opportunity with a CAGR of 15% to 20% over the planning period, focusing on high-potential accounts and expanding into new markets like prostatectomy.
---
AXGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AXGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $18.01 | $20.11 | +11.66% |
| Nov 07, 2024 | $15.33 | $13.27 | -13.44% |
| Aug 08, 2024 | $7.92 | $10.70 | +35.10% |
| May 02, 2024 | $6.56 | $5.88 | -10.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AxoGen (AXGN) report earnings?
AxoGen (AXGN) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is AxoGen (AXGN) earnings time?
AxoGen (AXGN) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXGN EPS forecast?
AXGN EPS forecast for the fiscal quarter 2025 (Q1) is 0.02.
---